1.13
-8.87%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aptevo Therapeutics
From its filings with the US Securities and Exchange Commission
Aptevo Therapeutics is based in Seattle, Washington and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker APVO. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2022, it reported revenue of $3.1m.
We are a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. We have developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs and have two clinical candidates and six preclinical candidates currently in development. Clinical candidate mipletamig is a CD123xCD3 T cell engager currently being clinically evaluated in the RAINIER trail, part one of a Phase 1b/2 program initiated in August 2024 for the treatment of frontline acute myelogenous leukemia (AML) in combination with standard of care venetoclax + azacitidine. Clinical candidate ALG.APV-527 targets 4-1BB (co-stimulatory receptor) and 5T4 (tumor antigen). The compound is designed to reactivate antigen-primed T cells to specifically kill tumor cells and is currently being evaluated for the treatment of multiple solid tumor types, potentially including breast, cervical, non-small- cell-lung, prostate, renal, gastric, colorectal and bladder cancers.
Along with our two clinical candidates, we have six preclinical candidates. All eight molecules were developed using our proprietary ADAPTIR and ADAPTIR-FLEX protein technology platforms. We wholly own both platforms. This enables us to efficiently design and create new molecules and support long-term growth. Based on the safety and tolerability results from mipletamig, which utilizes a unique and proprietary CRIS-7 binding domain, the Company has built out its CD3 engaging portfolio to five molecules.
Quoted from its 10-K, filed 26 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Jul 2016
- Employees
- 33
- Website
- aptevotherapeutics.com ↗
- Head office
- 2401 4TH AVE., SEATTLE, WA, 98121
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. John NiederhuberIndependent Chairman of the Board$83,038
- Mr. Marvin WhitePresident, Chief Executive Officer, Director, since 2016$906,020
- Ms. Daphne TaylorChief Financial Officer, Senior Vice President
- Mr. Jeffrey LamotheChief Operating Officer, Executive Vice President$708,264
- Ms. So Young KwonSenior Vice President, General Counsel, Business Development and Corporate Affairs$641,672
- Mr. Daniel Abdun-NabiIndependent Director$68,038
- Mr. Grady GrantIndependent Director$65,538
- Dr. Zsolt HarsanyiIndependent Director$88,038
- Ms. Barbara KunzIndependent Director$73,038
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aptevo Therapeutics focuses on oncology and hematology therapeutics with four products in development.
- The ADAPTIR platform enables production of monospecific and multispecific immunotherapeutic proteins.
- WinRho SDF, HepaGam B, and VARIZIG are marketed products in hematology and infectious diseases.
Weaknesses
- Aptevo has only 33 employees, which is low for a clinical-stage biotechnology company.
- The company's IPO was in 2016, indicating limited recent market presence.
- Aptevo's products are primarily in investigational stages with no commercialized oncology drugs.
Opportunities
- Aptevo's ADAPTIR platform could expand into new immuno-oncology applications.
- The hematology and infectious disease markets offer growth potential for WinRho SDF and HepaGam B.
- Aptevo's investigational products like MOR209/ES414 may attract partnerships or acquisitions.
Threats
- Aptevo faces competition from established biotechnology firms in oncology.
- The clinical-stage development of products carries high risk of failure.
- Regulatory approval delays could impact the commercialization timeline for new products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.